These in vivo results are quite in line with the in vitro findings and strongly suggest involvement of GLUT1-mediated glucose metabolism in gefitinib resistance of NSCLC not only in vitro but also in vivo. Here, SLC2A1 is linked to non-small cell lung carcinoma.